Drugs & Targets FDA publishes updated CAR T regulatory framework December 12, 2025Vol.51 No.45By Jacquelyn Cobb
Drugs & Targets Augmentin XR becomes first drug to receive FDA approval through Commissioner’s National Priority Voucher Pilot Program December 12, 2025Vol.51 No.45
Drugs & Targets FDA grants Breakthrough Therapy designation for Tecvayli + Darzalex Faspro as a second line treatment for r/r MM December 12, 2025Vol.51 No.45
Drugs & Targets FDA approves robotic-assisted surgery system for urologic surgical procedures December 12, 2025Vol.51 No.45
Drugs & Targets FDA approves first CAR T-cell therapy for marginal zone lymphoma December 12, 2025Vol.51 No.45
Drugs & Targets FDA approves Keytruda and Keytruda Qlex + Padcev as perioperative treatment cisplatin-ineligible bladder cancer December 05, 2025Vol.51 No.44
Drugs & Targets FDA grants 501(k) clearance for Vanquish System for prostate tissue ablation in intermediate risk prostate cancer December 05, 2025Vol.51 No.44
Drugs & Targets FDA approves durvalumab + FLOT for resectable gastric or gastroesophageal junction adenocarcinoma December 05, 2025Vol.51 No.44
Drugs & Targets EC approves expanded use of CAR T-cell therapy Breyanzi for r/r mantle cell lymphoma December 05, 2025Vol.51 No.44
Drugs & Targets Université Paris-Saclay, Owkin partner to use AI co-pilot for biology research December 05, 2025Vol.51 No.44
